Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy

por Crane, Christopher H., Varadhachary, Gauri R., Wolff, Robert A., Fleming, Jason B.
Publicado 2009

Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma

por Raghav, Kanwal, Liu, Suyu, Overman, Michael, Morani, Ajaykumar, Willette, Anneleis, Fournier, Keith, Varadhachary, Gauri
Publicado 2021

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay

por Raghav, Kanwal, Overman, Michael, Poage, Graham M., Soifer, Harris S., Schnabel, Catherine A., Varadhachary, Gauri R.
Publicado 2020

A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable...

por Katz, Matthew, Todd, Bauer W, Varadhachary, Gauri, Acquavella, Nicolas, Petroni, Gina, Bullock, Timothy, Slingluff, Craig L, Rahma, Osama
Publicado 2015

Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait

por Huey, Ryan W., Makawita, Shalini, Xiao, Lianchun, Matamoros, Aurelio, Estrella, Jeannelyn S., Overman, Michael J., Varadhachary, Gauri R., Raghav, Kanwal
Publicado 2019

Cancer of Unknown Primary Presenting as Bone‐Predominant or Lymph Node‐Only Disease: A Clinicopathologic Portrait

por Huey, Ryan W., Smaglo, Brandon G., Estrella, Jeannelyn S., Matamoros, Aurelio, Overman, Michael J., Varadhachary, Gauri R., Raghav, Kanwal P.S.
Publicado 2021

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater

por Gulhati, Pat, Raghav, Kanwal, Shroff, Rachna, Varadhachary, Gauri, Javle, Milind, Qiao, Wei, Wang, Huamin, Morris, Jeffrey, Wolff, Robert, Overman, Michael J.
Publicado 2017

Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes

por Raghav, Kanwal, Mhadgut, Hemendra, McQuade, Jennifer L., Lei, Xiudong, Ross, Alicia, Matamoros, Aurelio, Wang, Huamin, Overman, Michael J., Varadhachary, Gauri R.
Publicado 2016

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

por Abdel-Wahab, Reham, Varadhachary, Gauri R., Bhosale, Priya R., Wang, Xuemei, Fogelman, David R., Shroff, Rachna T., Overman, Michael J., Wolff, Robert A., Javle, Milind
Publicado 2018

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

por Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L
Publicado 2010

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma

por Overman, Michael J., Soifer, Harris S., Schueneman, Aaron Joel, Ensor, Joe, Adsay, Volkan, Saka, Burcu, Neishaboori, Nastaran, Wolff, Robert A., Wang, Huamin, Schnabel, Catherine A., Varadhachary, Gauri
Publicado 2016

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival

por Nystrom, J. Scott, Hornberger, John C., Varadhachary, Gauri R., Hornberger, Richard J., Gutierrez, Hialy R., Henner, W. David, Becker, Shawn H., Amin, Mahul B., Walker, Michael G.
Publicado 2012

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

por Douglas, Julia E., Liu, Suyu, Ma, Junsheng, Wolff, Robert A., Pant, Shubham, Maitra, Anirban, Tamm, Eric P., Bhosale, Priya, Katz, Matthew H. G., Varadhachary, Gauri R., Koay, Eugene J.
Publicado 2022

Concurrent capecitabine and upper abdominal radiation therapy is well tolerated

por Das, Prajnan, Wolff, Robert A, Abbruzzese, James L, Varadhachary, Gauri R, Evans, Douglas B, Vauthey, Jean Nicolas, Baschnagel, Andrew, Delclos, Marc E, Krishnan, Sunil, Janjan, Nora A, Crane, Christopher H
Publicado 2006

Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma

por Liu, Qingqing, Stewart, John, Wang, Hua, Rashid, Asif, Zhao, Jun, Katz, Matthew H., Lee, Jeffrey E., Fleming, Jason B., Maitra, Anirban, Wolff, Robert A., Varadhachary, Gauri R., Krishnan, Sunil, Wang, Huamin
Publicado 2017

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

por Fogelman, David R., Holmes, Holly, Mohammed, Khalil, Katz, Matthew H. G., Prado, Carla M., Lieffers, Jessica, Garg, Naveen, Varadhachary, Gauri R., Shroff, Rachna, Overman, Michael J., Garrett, Christopher, Wolff, Robert A., Javle, Milind
Publicado 2014

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

por Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia
Publicado 2020

Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome

por Overman, Michael J., Zhang, Jiexin, Kopetz, Scott, Davies, Michael, Zhi-Qin, Jiang, Stemke-Hale, Katherine, Rümmele, Petra, Pilarsky, Christian, Grützmann, Robert, Hamilton, Stanley, Hwang, Rosa, Abbruzzese, James L., Varadhachary, Gauri, Broom, Bradley, Wang, Huamin
Publicado 2013

Correction: Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome

por Overman, Michael J., Zhang, Jiexin, Kopetz, Scott, Davies, Michael, Jiang, Zhi-Qin, Stemke-Hale, Katherine, Rümmele, Petra, Pilarsky, Christian, Grützmann, Robert, Hamilton, Stanley, Hwang, Rosa, Abbruzzese, James L., Varadhachary, Gauri, Broom, Bradley, Wang, Huamin
Publicado 2013

Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC

por Colbert, Lauren E., Moningi, Shalini, Chadha, Awalpreet, Amer, Ahmed, Lee, Yeonju, Wolff, Robert A., Varadhachary, Gauri, Fleming, Jason, Katz, Matthew, Das, Prajnan, Krishnan, Sunil, Koay, Eugene J., Park, Peter, Crane, Christopher H., Taniguchi, Cullen M.
Publicado 2017